Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals' stock has been positively impacted by investor reaction to deal-making and sales updates, resulting in significant share price returns and analyst upgrades. The company reported strong third-quarter 2025 earnings, exceeding expectations and increasing quarterly revenue. The acquisition of Bluejay Therapeutics in January 2026, adding a late-stage hepatitis D candidate, was viewed positively. The FDA approved CTEXLI for cerebrotendinous xanthomatosis (CTX) in February 2025 and a tablet formulation of Livmarli in April 2025. There have been reports of insider selling by executives in early February 2026.

Based on the available information, there is no clear indication of significant demand seasonality for Mirum Pharmaceuticals' products and services. Revenue variability is more likely due to order patterns rather than inherent seasonal demand.

Mirum Pharmaceuticals is dedicated to developing and commercializing novel therapies for debilitating rare and orphan liver diseases, focusing on unmet medical needs in pediatric and adult populations. Its major products include LIVMARLI (maralixibat), approved for treating cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), with a tablet formulation approved in April 2025. Volixibat is in Phase 2b trials for Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis (PBC). CHOLBAM (cholic acid capsules) is approved for treating bile acid synthesis disorders and as an adjunctive treatment for peroxisomal disorders. CTEXLI (chenodiol tablets) is approved for treating radiolucent stones in the gallbladder and cerebrotendinous xanthomatosis (CTX). Brelovitug was added to Mirum's pipeline through the acquisition of Bluejay Therapeutics in January 2026, targeting chronic hepatitis delta virus (HDV).

Mirum Pharmaceuticals is headquartered in Foster City, California, United States, and has an international presence with LIVMARLI approved for use in the U.S., Europe, and other regions globally. The company is actively expanding its treatment indications across different regions and age groups.

Mirum Pharmaceuticals has cultivated a reputation as a high-growth rare disease company focused on commercializing life-changing medicines, prioritizing patient needs and developing innovative therapies for unmet medical needs. The company aims to be a global leader in developing treatments for rare liver diseases, with recent positive events contributing to a favorable brand perception.

Mirum Pharmaceuticals' ownership is heavily concentrated among institutional investors and funds, including Frazier Life Sciences Management, L.P., Janus Henderson Group Plc, BlackRock, Inc., and Vanguard Group Inc. CEO Chris Peetz held a direct ownership stake of 0.64% as of early 2025.